He YJ, Meghani K, Caron M-C, et al. DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells. Nature. 2018;563(7732):522-526. doi:10.1038/s41586-018-0670-5.

Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine. Genome Med. 2018;10(1):93. doi:10.1186/s13073-018-0605-7.

Rees MG, Seashore-Ludlow B, Clemons PA. Computational Analyses Connect Small-Molecule Sensitivity to Cellular Features Using Large Panels of Cancer Cell Lines. Methods Mol Biol. 2019;1888:233-254. doi:10.1007/978-1-4939-8891-4_14.

Frangieh CJ, Melms JC, Thakore PI, et al. Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion. Nat Genet. 2021;53(3):332-341. doi:10.1038/s41588-021-00779-1.

Oser MG, Fonseca R, Chakraborty AA, et al. Cells Lacking the Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov. 2019;9(2):230-247. doi:10.1158/2159-8290.CD-18-0389.

Guerra RM, Bird GH, Harvey EP, et al. Precision Targeting of BFL-1/A1 and an ATM Co-dependency in Human Cancer. Cell Rep. 2018;24(13):3393-3403.e5. doi:10.1016/j.celrep.2018.08.089.

Hamieh L, Choueiri TK, Ogórek B, et al. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genet. 2018;14(9):e1007679. doi:10.1371/journal.pgen.1007679.

Hacken ET, Valentin R, Regis FFD, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018;3(19). doi:10.1172/jci.insight.121438.

Kitajima S, Asahina H, Chen T, et al. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell. 2018;34(3):439-452.e6. doi:10.1016/j.ccell.2018.08.009.

Landau DA, Sun C, Rosebrock D, et al. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nat Commun. 2017;8(1):2185. doi:10.1038/s41467-017-02329-y.